Studies indicate that upregulating CD163 expression inmicroglia/macrophages after ICH through activation of the PPAR-γ pathway(via PPAR-γ agonist monascin and chemokine fractalkine) or the Nrf2pathway (via C-C motif chemokine ligand 17) promotes hematoma clearance [72, 73, 74].However, Leclerc et al. [75] revealed a biphasic role of CD163deficiency in ICH, with early protective effects shifting to later detrimentalconsequences. This evidence concerns the gene CD163 and hematoma.